Page last updated: 2024-10-18

dalteparin and Purpura, Thrombotic Thrombocytopenic

dalteparin has been researched along with Purpura, Thrombotic Thrombocytopenic in 1 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Purpura, Thrombotic Thrombocytopenic: An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lucania, G1
Camiolo, E1
Carmina, MG1
Fiandaca, T1
Indovina, A1
Malato, A1
Messina, R1
Fabbiano, F1
Marcenò, R1

Other Studies

1 other study available for dalteparin and Purpura, Thrombotic Thrombocytopenic

ArticleYear
Multidisciplinary approach in pregnancy-associated thrombotic thrombocytopenic purpura: a case report.
    Blood transfusion = Trasfusione del sangue, 2014, Volume: 12 Suppl 1

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Cesarean Section; Combined Modality T

2014